NASDAQ$VRDN
Viridian Therapeutics Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Announced first quarter 2021 financial results and provided corporate updates.
Viridian Therapeutics reported its first quarter 2021 financial results, highlighting progress in its VRDN-001 and VRDN-002 programs for Thyroid Eye Disease (TED) and a cash position of $117 million. The company's net loss for the quarter was $18.5 million, with increased R&D and G&A expenses compared to the same period in 2020.
- VRDN-001 and VRDN-002 programs for Thyroid Eye Disease (TED) are progressing as planned, with IND filings expected in the fourth quarter of 2021.
- The company reported $117.1 million in cash, cash equivalents, and short-term investments as of March 31, 2021, providing a cash runway into 2024.
- Research and development expenses increased to $13.8 million, driven by the advancement of lead programs.
- Net loss for the quarter was $18.5 million, compared to $8.0 million for the same quarter in the previous year.
Headline financials
Revenue & EPS history
Viridian Therapeutics · Revenue · Quarterly
$1.45M
Revenue by segment
Viridian Therapeutics · $98K total across 1 segment · Q1 2023
- Collaboration Revenue - related party$98K—100.0%
Forward guidance
Viridian Therapeutics is focused on advancing its VRDN-001 and VRDN-002 programs for TED, with IND filings expected in Q4 2021 and clinical data anticipated in 2022. The company is also expanding its discovery pipeline and believes its current cash position will fund operations into 2024.
Tailwinds
- On track for IND filings for VRDN-001 and VRDN-002 in Q4 2021.
- Initial proof of concept data for VRDN-001 in patients expected in Q2 2022.
- Phase 1 trial data for VRDN-002 expected in mid-year 2022.
- Dosing of patients in VRDN-002 trials expected to initiate in 2022.
- Cash runway sufficient to fund operations into 2024.
Headwinds
- Uncertainty and potential delays related to clinical drug development.
- Impact of regulatory delays on clinical programs.
- Manufacturing risks associated with product candidates.
- Competition from other therapies or products.
- Effects from the COVID-19 pandemic on research, development, and business activities.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
+2.0%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+1.6%
Avg return
30 days after
49%
23 / 47 earnings
Positive
+73.1%
Q2 2022
Best reaction
-23.7%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +33.5% | +18.2% | +17.9% | |
| Q4 2025 | +1.9% | +1.3% | -5.4% | |
| Q3 2025 | +8.3% | +22.6% | +42.0% | |
| Q1 2025 | +2.6% | +8.2% | +25.8% | |
| Q4 2024 | +1.6% | -0.1% | -5.6% | |
| Q3 2024 | -12.6% | -21.7% | -30.0% | |
| Q2 2024 | -2.5% | -4.5% | -8.5% | |
| Q1 2024 | -8.1% | -5.3% | -19.6% | |
| Q4 2023 | +4.7% | +3.2% | -9.1% | |
| Q3 2023 | +10.6% | +15.4% | +39.8% | |
| Q2 2023 | +8.6% | +10.6% | +5.6% | |
| Q1 2023 | -0.5% | -8.1% | -0.1% | |
| Q4 2022 | -11.0% | -12.4% | -22.8% | |
| Q3 2022 | +11.4% | +9.9% | +36.1% | |
| Q2 2022 | +73.1% | +60.1% | +56.1% | |
| Q1 2022 | +35.1% | +44.3% | +8.6% | |
| Q4 2021 | +2.2% | +1.4% | -5.3% | |
| Q3 2021 | +6.0% | +2.1% | +5.1% | |
| Q2 2021 | -15.5% | -18.4% | -12.4% | |
| Q1 2021 | -4.4% | -9.4% | -12.4% | |
| Q4 2020 | +3.4% | -4.9% | +5.5% | |
| Q3 2020 | -4.4% | -6.9% | +14.9% | |
| Q2 2020 | -4.4% | +1.8% | -21.1% | |
| Q1 2020 | +3.5% | +20.2% | +52.6% | |
| Q4 2019 | -23.7% | -37.1% | -31.0% | |
| Q3 2019 | -3.2% | -19.2% | -21.9% | |
| Q2 2019 | -2.3% | -7.5% | -18.0% | |
| Q1 2019 | -0.4% | -2.5% | -17.4% | |
| Q4 2018 | +6.2% | +11.3% | +15.6% | |
| Q3 2018 | -5.3% | -17.2% | -27.5% | |
| Q2 2018 | -8.0% | -7.5% | -7.5% | |
| Q1 2018 | -0.5% | +2.1% | -2.0% | |
| Q4 2017 | +3.1% | +7.5% | -7.8% | |
| Q3 2017 | -3.1% | -11.2% | +0.3% | |
| Q2 2017 | -12.6% | -13.5% | -17.9% | |
| Q1 2017 | +2.2% | +2.1% | -16.7% | |
| Q4 2016 | +10.9% | +6.4% | +5.9% | |
| Q3 2016 | +7.3% | -10.2% | +57.7% | |
| Q2 2016 | +1.2% | -3.7% | -6.1% | |
| Q1 2016 | -1.6% | — | — | |
| Q4 2015 | -0.4% | — | — | |
| Q3 2015 | -5.0% | — | — | |
| Q2 2015 | -10.6% | — | — | |
| Q1 2015 | -6.8% | — | — | |
| Q4 2014 | -5.4% | — | — | |
| Q3 2014 | +1.6% | — | — | |
| Q2 2014 | +9.5% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro